Condition: Relapsed · Refractory · Multiple Myeloma · Sponsor: Shanghai Cell Therapy Group Co.,Ltd
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.
This description comes directly from the study's public registry record.
Jinxing Lou · 0086-021-67091399 · loujx@shcell.com
Jinxing Lou · loujx@shcell.com
Always discuss trial participation with your own doctor first.
| China, Shanghai Mengchao Cancer Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06732232